3D生物打印药物筛选生理病理模型平台建立的研究进展

高通量药物筛选是新药研发的重要方法,通过3D生物打印相关的组织模型,在疾病建模和高通量药物筛选中具有巨大的潜力和发展前景。而生物墨水相对匮乏,体外制造的组织器官的存活时间相对较短,是制约3D生物打印药物筛选平台建立及快速发展的瓶颈。目前,研究者们已经将3D生物打印药物筛选生理病理模型应用在血管、心脏、肝脏、肾脏、肿瘤等领域。与传统的生物制造方法相比,3D生物打印技术具有选择范围广、筛选成本较低、结果可靠等特点,是新药研究的重要手段,在药物研发中前景广阔。在中医中药领域,它可以加快中医中药的深入研究,利于发现中医中药在疾病治疗过程中的作用机制。但该技术仍然存在缺陷,目前3D生物打印仍然缺乏有说服力的产品,还需要更多的证据来证实其构造出的模型在药物的研究中具备和体内一致的性能。

Advances in the Establishment of a 3D Bioprinting Drug Screening Physiological and Pathological Model Platform

High-throughput drug screening is an important method for the development of new drugs. Tissue model of related functions by 3D bioprinting, it has great potential and development prospects in pathological model created and high-throughput drug screening. The bio-ink is relatively scarce, and the survival time of tissues and organs manufactured in vitro is relatively short, which is the bottleneck restricting the establishment and rapid development of the 3D bio-printing drug screening platform. At present, researchers have applied 3D bioprinting drug screening physiological and pathological models to blood vessels, heart, liver, kidney, tumor and other fields. Compared with traditional bio-manufacturing methods, 3D bio-printing technology has the characteristics of wide selection, low screening cost and reliable results. It is an important means of new drug research and has broad prospects in drug development. In the field of traditional Chinese medicine, it can speed up the in-depth study of traditional Chinese medicine, and help to discover the mechanism of Chinese medicine in the course of disease treatment. However, this technology still has defects. At present, 3D bioprinting still lacks convincing products, and more evidence is needed to demonstrate that the constructed model platform has consistent performance compared to the human body in the drug research.